Treatment-based literature of Henoch-Schönlein purpura nephritis in childhood.
Considerable concern has been expressed on the importance of identifying an improved therapeutic protocol for use in the treatment of childhood Henoch-Schönlein purpura nephritis, primarily due to the unpredictable success shown to date in improving long-term renal outcome. This review focuses on published reports describing the outcomes of therapeutic approaches currently being used in the treatment of pediatric Henoch-Schönlein purpura nephritis, with the aim of providing information that will facilitate a treatment-based approach in children presenting with varying degrees of kidney disease. The conclusions of the authors of this review are that currently prescribed treatments of children affected by Henoch-Schönlein purpura nephritis are not adequately guided by evidence obtained in properly designed, randomized, placebo-controlled trials with outcome markers related to the progression to end stage renal disease (level I evidence). Moreover, firm evidence supporting the best practice to be applied with the aim of delaying the progression of kidney disease is still lacking.
Zaffanello
Marco
M
Department of Mother-Child and Biology-Genetics, University of Verona, 37134 Verona, Italy. marco.zaffanello@univr.it
Fanos
Vassilios
V
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D006801:Humans; D011695:IgA Vasculitis / Q000150:complications / Q000188:drug therapy; D007223:Infant; D009393:Nephritis / Q000188:drug therapy* / Q000209:etiology